SLXN Initiates Phase 2/3 Trial
Silexion Therapeutics receives approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.